Dr. Joseph Tucker joined Ventac Partners as Partner in December 2015. He has more than 15 years experience in senior life science and finance roles in both the United States and Canada. Key past executive positions include Chief Executive Officer at Stem Cell Therapeutics Inc. and Pharmavation Inc., Chief Financial Officer at SolAeroMed Inc., and Vice President at Resverlogix Inc. and Neurostasis Inc. Joseph began his career as a health care stock market analyst.
Dr. Tucker’s core skills lie in executive management, company creation, business development, and intellectual property protection. As Chief Executive Officer and co-founder of Stem Cell Therapeutics, Joseph led the company through several rounds of fund-raising and a successful Initial Public Offering. Other exits of co-founded companies include the out-licensing of Pharmavation to Affectis and the sale of Neurostasis to Transition Therapeutics. Dr. Tucker is also an inventor of more than 20 issued or pending patents.
Currently, Dr. Tucker holds Chief Executive Officer roles at Epimeron Inc. and Taiga Bioactives Inc. In addition, he lectures in the Masters of Biomedical Technology program at the University of Calgary and is a board member of BioAlberta. In 2005 he was nominated in Canada for Entrepreneur of the Year in the Life Science field, and in 2007 he received a Canada’s Top 10 Companies – Life Sciences award for his work with Stem Cell Therapeutics.
Dr. Tucker has a B.Sc. in Cellular, Molecular, and Microbial Biology and a Ph.D. in Biochemistry and Molecular Biology, both from the University of Calgary.